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ABSTRACT Parkinson’s disease (PD), a neurodegen-
erative disorder, causes severe motor impairment due
to loss of dopaminergic neurons in substantia nigra
pars compacta (SNpc). MPTP, a neurotoxin that causes
dopaminergic cell loss in mice, was used in an animal
model to study the pathogenic mechanisms leading to
neurodegeneration. We observed the activation of ap-
optosis signal regulating kinase (ASK1, MAPKKK) and
phosphorylation of its downstream targets MKK4 and
JNK, 12 h after administration of a single dose of
MPTP. Further, Daxx, the death-associated protein,
translocated to the cytosol selectively in SNpc neurons
seemingly due to MPTP mediated down-regulation of
DJ-1, the redox-sensitive protein that binds Daxx in the
nucleus. Coadministration of -lipoic acid (ALA), a
thiol antioxidant, abolished the activation of ASK1 and
phosphorylation of downstream kinases, MKK4, and
JNK and prevented the down-regulation of DJ-1 and
translocation of Daxx to the cytosol seen after MPTP.
ALA also attenuated dopaminergic cell loss in SNpc
seen after subchronic MPTP treatment. Our studies
demonstrate for the first time that MPTP triggers death
signaling pathway by activating ASK1 and translocating
Daxx, in vivo, in dopaminergic neurons in SNpc of mice
and thiol antioxidants, such as ALA terminate this
cascade and afford neuroprotection.—Karunakaran,
S., Diwakar, L., Saeed, U., Agarwal, V., Ramakrishnan,
S., Iyengar, S., Ravindranath, V. Activation of apoptosis
signal regulating kinase 1 (ASK1) and translocation of
death associated protein, Daxx in substantia nigra pars
compacta in a mouse model of Parkinson’s disease:
Protection by -lipoic acid. FASEB J. 21, 2226–2236
(2007)
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Neurodegenerative disorders are a heterogeneous
group of disorders with onset typically in the fifth to
seventh decade of life. They are progressive in nature
and affect selective regions of the CNS. A common
pathological hallmark of neurodegenerative disorders
such as amyotrophic lateral sclerosis, Alzheimer’s dis-
ease, Huntington’s disease, and Parkinson’s disease
(PD) is the loss of subsets of neurons within specific
regions of the CNS. Severe motor impairment is seen in
PD, the second most common neurodegenerative dis-
order after Alzheimer’s disease. The clinical symptoms
include bradykinesia, rigidity, and resting tremor. PD is
associated with a profound and selective loss of dopa-
minergic neurons in the substantia nigra pars compacta
(SNpc) of the midbrain and the dopaminergic termi-
nals in the striatum. At the time of clinical presentation,
50–70% of dopaminergic neurons in the nigrostriatal
system are lost (1). Oxidative stress and mitochondrial
dysfunction caused by loss of complex I activity are
identified as some of the primary events leading to
neurodegeneration in PD.
Exposure to MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tet-
rahydropyridine), a model neurotoxin leads to loss of
dopaminergic neurons in SNpc in mice in a manner
similar to that seen in Parkinson’s disease. MPTP is,
therefore, used as a model neurotoxin to study the
molecular events that cause degeneration of dopami-
nergic neurons in Parkinson’s disease (2). In the brain,
MPTP is oxidized by monoamine oxidase B to MPP,
the ultimate toxic metabolite. MPP is a high-affinity
substrate for the dopamine transporter (3) and is taken
up selectively into dopaminergic neurons. MPP gen-
erates oxidative stress and impairs oxidative phosphor-
ylation by inhibiting complex I of the mitochondrial
electron transport chain (4), leading to rapid decrease
in ATP content in the striatum and ventral midbrain,
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the brain regions most sensitive to MPTP toxicity (5).
Significant ATP depletion can result from as little as
25% inhibition of complex I (6), indicating a causal
relationship between complex I activity and ATP pro-
duction in mitochondria.
Earlier studies from our laboratory have demon-
strated that administration of MPTP to male mice
results in loss of the antioxidant thiol glutathione,
measured as sum of oxidized (GSSG) and reduced
GSH, which precedes the inhibition of mitochondrial
complex I activity in midbrain (7). Complex I inhibi-
tion caused by MPTP can be reversed by dithiothreitol,
providing further evidence that protein thiol oxidation
is a primary cause for complex I inhibition (8). More
recently we have also demonstrated that glutaredoxin
(also known as thioltransferase; Grx1), a thiol-disulfide
oxidoreductase that efficiently and specifically reduces
glutathione-containing mixed disulfides (9), is re-
quired for maintenance of complex I function in
normal conditions. Its upregulation is critical for the
recovery of complex I function following MPTP admin-
istration, indicating that complex I dysfunction follow-
ing MPTP presumably occurs through glutathionyla-
tion of its critical thiol groups.
Generally, oxidative stress in brain results in exten-
sive oxidative modification of protein thiols at available
cysteine residues in proteins (10). Although such oxi-
dative modification of thiols, including glutathionyla-
tion of proteins, is seen in certain cells of non-neural
origin (11), it is more pronounced in brain, presum-
ably because extrusion of GSSG, as routinely observed
in other tissues such as lung and liver is not always seen
in brain (12). Oxidative modification of protein thiol
groups, through formation of mixed disulfides, can
impair the functional characteristics of critical proteins.
For example, formation of PrSSG can potentially dis-
rupt mitochondrial function by cross-linking sulfhydryl
groups, resulting in the opening of the mitochondrial
permeability transition pore (13). More importantly,
redox status of critical thiol groups in signaling mole-
cules such as kinases and phosphatases often determine
the initiation and progression of signaling cascades,
which decide cell fate in terms of activating and prop-
agating death vs. survival pathways (14). Thus, ASK1,
a mitogen-activated protein kinase kinase kinase
(MAPKKK) exists in cells in association with thiore-
doxin (Trx), which prevents it from autophosphoryla-
tion. Oxidative modification of thioredoxin results in
its dissociation from ASK1 leading to activation of ASK1
by autophosphorylation (15, 16). ASK1 then initiates
the MAP kinase cascade, leading to the phosphoryla-
tion of c-Jun N-terminal kinase (JNK). Most of the
existing knowledge on redox signaling has emerged
from the cultured cell systems following overexpression
of recombinant proteins. However, their physiological
relevance, in vivo, remains to be established.
In the current study, we examined the status of the
MAP kinase-signaling cascade in striatum and ventral
midbrain following administration of MPTP to mice. In
addition, we coadministered the thiol antioxidant, -li-
poic acid (ALA) with MPTP and examined its effect on
the MAPK signaling and subsequent neuroprotection.
MATERIALS AND METHODS
Materials
The antibodies to Daxx (M-112, polyclonal), ASK-1 (H-300,
polyclonal), pJNK (G-7, monoclonal), and DJ-1 (C-16, poly-
clonal) were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA). Antibody to -tubulin was obtained
from Sigma-Aldrich (St. Louis, MO, USA). Antibody to lamin
A/C and phospho-SEK1/MKK4 (Thr261) were purchased
from Cell Signaling Technology, Inc. (Danvers, MA, USA).
Vectastain-ABC Elite kit was purchased from Vector labs
(Burlingame, CA, USA). All other chemicals and reagents
were of analytical grade and were obtained from Sigma
Aldrich or Qualigens (India).
Animals
All animal experiments were carried out as per the institu-
tional guidelines for the use and care of animals. All efforts
were made to minimize animal suffering, to reduce the
number of animals used, and to utilize alternatives to in vivo
techniques if available. Male C57BL6J and Swiss albino mice,
(2 to 3 mo, 25–30 g) were obtained from National Brain
Research Centre (NBRC) and Central Animal Research Fa-
cility of National Institute of Mental Health and Neuro-
sciences (NIMHANS). Animals were given MPTP (30 mg/kg
body weight) subcutaneously. Animals had access to pelleted
diet and water ad libitum. Animals were also administered with
sodium salt of -lipoic acid (ALA; 22 mg/kg body weight, s.c.)
twice daily. Control animals received vehicle alone. At the end
of the experimental period, mice were anesthetized with
ether and perfused transcardially with ice-cold normal saline
before decapitation. Ventral midbrain was dissected as de-
scribed (Fig. 1). Ventral midbrain and striatum were frozen in
liquid nitrogen for immunoblotting, assay of GSH and com-
plex I activity. Animals were perfused transcardially with
buffered paraformaldehyde (4% w/v), and the brain was
dissected out and processed for immunohistochemistry. All
experiments were carried out on C57 black mice unless
indicated otherwise. Brain regions from 2–3 animals were
pooled for each sample.
Processing of tissue
Tissue was homogenized in 0.25 M sucrose and centrifuged at
1000 g for 10 min to obtain postnuclear supernatant. The
postnuclear supernatant was used for immunoblotting. Post-
nuclear supernatant was centrifuged again at 14,000 g for 30
min to obtain the mitochondrial pellet. The pellet was
suspended in sucrose (0.25 M) and freeze-thawed for assay of
complex I. The postnuclear supernatant was also centrifuged
at 100,000 g for 30 min to obtain cytosol, which was used for
estimation of cystathionine--lyase activity. Protein concentra-
tion was estimated by a dye-binding method (17). For the
assay of GSH, tissues were frozen immediately in liquid
nitrogen and homogenized in 9 volumes of 100 mM potas-
sium phosphate buffer (pH 7.4) containing 1 mM EDTA. An
aliquot of homogenate was added to an equal volume of
5-sulfosalicylic acid (1%, w/v), mixed and centrifuged at
10,000 g for 10 min, and the supernatant was used for
estimation of total GSH and the pellet for PrSSG using HPLC.
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Estimation of total GSH and PrSSG
GSH and PrSSG were estimated by HPLC following derivati-
zation with fluorodinitrobenzene (FDNB) (18) using -glu-
tamylglutamate (-Gluglu) as internal standard. For assay of
GSH, the acid-soluble supernatant was treated with FDNB and
used directly for HPLC analysis. For assay of PrSSG, the
acid-insoluble pellet was washed with ethanol and treated
with MOPS-dithiothreitol buffer to reduce PrSSG to protein
thiol (18). The GSH thus released was derivatized and
subjected to HPLC analysis.
Estimation of MPP
Ventral midbrain was dissected out from animals treated with
MPTP alone or ALA and MPTP for 1 and 12 h as described
above. The brain tissue was homogenized in potassium phos-
phate buffer (50 mM, pH 7.4), mixed with methanol (1:1
v/v), vortexed, centrifuged at 14000 g, and filtered through
0.45 m membrane. The filtrate (100 l) was injected into
HPLC column (SUPELCOSIL, LC-CN). The mobile phase
consisted of 0.1 M sodium acetate buffer (pH 7.2) containing
10% acetonitrile (v/v), 0.1% triethylamine (v/v), and tetra-
ethyl ammonium bromide (0.01%, w/v). MPP was detected
using UV detector set at 292 nm (19) and quantitated from
the standard curve run using known concentrations of MPP.
Assay of NADH: ubiquinone oxido-reductase
(complex I) activity
Complex I was assayed in mitochondrial preparations as
rotenone-sensitive NADH-ubiquinone oxido-reductase (20).
The assay was performed in 35 mM potassium phosphate
buffer (pH 7.4) containing sodium cyanide (2.65 mM),
magnesium chloride (5 mM), EDTA (1 mM), bovine serum
albumin (1 mg/ml), and antimycin (2 g/ml). Brain mito-
chondria (70–80 g) and ubiquinone 1 (0.05 mM) were
added to the assay buffer to a final volume of 0.48 ml. After
preincubation of the reaction mixture at room temperature
for 2 min, the reaction was initiated by addition of 0.02 ml of
5 mM NADH solution. Test and blank reactions were run
separately. The rate of decrease of absorbance at 340 nm was
monitored over 3 min. The assay was also performed in the
presence of rotenone to determine rotenone-sensitive en-
zyme activity. Less than 2% of the total activity was rotenone
insensitive. The enzyme activity is expressed as nanomoles of
NADH oxidized/min/mg protein.
Assay of cystathionine--lyase
Cystathionine--lyase activity was measured in cytosol pre-
pared from mouse brain or liver (21). The reaction mixture
(total volume 0.5 ml) containing cytosolic protein from brain
(2 mg), 100 l Tris-HCl buffer (5 mM), and 10 l of pyridoxal
5-phosphate (1 mM) was considered as blank. The test
sample contained all the above and 10 l of L-cystathionine
(2 mM) as substrate. After 2 h of incubation at 37°C, the tubes
were placed in an ice-water bath at 4°C to terminate the
reaction. Dithiothreitol (5 mM, 10 l) was added to each tube
to reduce cystine to cysteine. Ninhydrin reagent was added to
the tubes and heated in boiling water bath for 10 min. Tubes
were cooled under tap water, and the absorbance of the pink
colored complex was measured at 560 nm by spectrophoto-
metric method (22) using cysteine as standard.
Immunohistochemistry and stereology
Male C57BL6J mice were administered MPTP (30 mg/kg
body weight/day, s.c.) once daily for 1 or 8 d. Control animals
received saline. Animals were anesthetized with ether 24 h
after the last injection and perfused transcardially with phos-
phate-buffered saline (PBS) followed by paraformaldehyde
(4%, w/v) in PBS and postfixed in paraformaldehyde. Cryo-
stat-cut coronal sections (30 m thick) were prepared
throughout the entire midbrain from a random start position,
and every fifth section was processed for tyrosine hydroxylase
immunohistochemistry. Sections were visualized after incuba-
tion with secondary antibody conjugated to FITC under
fluorescent microscope. Persons blind to the treatment
counted the number of tyrosine hydroxylase positive neurons
in the substantia nigra pars compacta (SNpc). Sections pass-
ing through rostral, middle and caudal regions of the SN,
were examined. The pars compacta region was delineated for
stereological counting. This delineation excluded pars reticu-
lata (SNR), ventral tegmental area and the retrorubral area.
For immunostaining of Daxx, sections were exposed to
hydrogen peroxide (3% v/v) to block the endogenous per-
oxidase reaction and then processed using antiserum to
Daxx. Finally, sections were washed, treated with biotinylated
anti-rabbit IgG (diluted 1: 500 in PBS) for 1 h, and incubated
with VECTASTAIN-Elite ABC reagent. The color was devel-
oped using diaminobenzidine and hydrogen peroxide. In a
separate set of experiments the immunostaining was visual-
ized using FITC labeled secondary antibody and the sections
were counterstained with DAPI.
Figure 1. Dissection of the ventral midbrain region from mice. Bregma coordinates and anatomic boundaries were established
for dissection of ventral midbrain based on the mouse brain atlas (42). Briefly, the skull plates were peeled away to visually locate
the bregma. The brain was removed from the skull and placed dorsal side up. Using a scalpel blade, a coronal cut was made
adjacent to the inferior colliculi approximately at bregma –6.36 mm. A second cut was made approximately at bregma –2.54
mm, depicted by solid lines in (A) and (B). The slice was placed rostral side up as indicated in (C). The ventral midbrain was
dissected out as indicated by solid lines in (C) ensuring that there was no contamination of the hippocampus, cortex or
cerebellum. The arrows in (C) indicate substantia nigra pars compacta.
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Studies with SH-SY5Y cells
SH-SY5Y cells were cultured in MEM (Gibco BRL) supple-
mented with 10% FBS. Cells were seeded in chamber slide at
70% confluency prior to treatment with MPP (3 mM) for
12 h. In experiments showing reversal of Daxx translocation,
cells were treated with N-acetyl cysteine (100 M) and ALA
(100 M), 60 min prior to addition of MPP. Cells were then
washed with PBS and fixed with 4% paraformaldehyde at
room temperature for 30 min. Immunocytochemistry for
Daxx was performed after washing the cells with PBS and
permeabilization with digitonin (0.01%; w/v) followed by
overnight incubation with antiserum to Daxx. After washing,
cells were incubated with secondary antibody conjugated to
Alexa flour 594, washed, mounted in medium containing
DAPI, and visualized under a fluorescence microscope.
Immunoblotting
The postnuclear supernatant prepared from ventral midbrain
or striatum (20 g protein) of vehicle and treated mice was
resolved on 10% sodium dodecyl sulfate polyacrylamide gel
(23). Proteins were transferred to nitrocellulose membranes
(24), incubated with primary antibody (1:1000) followed by
secondary antibody (1:2000) labeled with alkaline phospha-
tase. Immunostained bands were detected using nitroblue
tetrazolium and 5-bromo 4-chloro 3-indolyl phosphate as
chromogens.
Statistical analysis
Statistical analysis of the data was performed using analysis of
variance followed by Student-Newman-keuls or Duncan’s test
or post hoc Students’ t test, as appropriate. Values of P  0.05
were taken as being statistically significant.
RESULTS
ALA reverses MPTP mediated activation of ASK1,
MKK4, and JNK
We examined the phosphorylation states of MAP ki-
nases following MPTP administration and further stud-
ied the effect of coadministration of -lipoic acid. Both
in striatum and ventral midbrain, we observed the
activation of ASK1 and phosphorylation of its down-
stream targets, MKK4 and JNK, 12 h after MPTP
administration. Animals treated with both ALA and
MPTP were similar to controls, and the phosphoryla-
tion states of MKK4 and JNK were unaffected (Fig. 2A,
B) indicating clearly that -lipoic acid prevents the
activation of the proapoptotic signaling pathway initi-
ated by ASK1. This is in consonance with our earlier
results that indicate that ALA helps maintain thiol
homeostasis in brain (25).
GSH and PrSSG levels in striatum and midbrain after
MPTP administration
GSH and PrSSG levels were estimated using HPLC in
striatum and midbrain regions of Swiss albino mice
treated with MPTP for 4 h (Fig. 3A). The chromato-
gram (Fig. 3A) from the striatum of vehicle and MPTP-
treated mice shows the internal standard -glutamylglu-
tamate (-Gluglu) followed by GSH or PrSSG assayed as
GSH, which were derivatized and separated as dinitro-
phenyl derivatives on octadecyl amino propyl column
by reverse-phase HPLC. MPTP administration leads to
loss of GSH and increase in GSH levels recovered as
PrSSG.
Decrease in GSH levels (32% in striatum and 21% in
midbrain) and increase in PrSSG (123% in striatum
and 118% in midbrain) were seen (Fig. 3B). In striatum
and midbrain the amount of GSH lost was essentially
recovered as PrSSG, indicating that MPTP exposure
results in significant perturbation of the GSH-protein
thiol homeostasis and extensive glutathionylation of
protein thiols.
Effect of L-propargylglycine on -cystathionase
activity, GSH levels, and complex I activity in
mouse brain
Propargyl glycine (PPG) inhibits cystathionine -lyase
(the rate-limiting enzyme in the conversion of methio-
nine to cysteine), resulting in impaired synthesis of
cysteine and thereby decreasing GSH synthesis (25, 26).
We examined the effect of PPG on GSH levels and
complex I activity in brain of Swiss albino mice. -Cys-
tathionase activity in brain was inhibited significantly
(68%) 18 h following a single dose of PPG (100 mg/kg
Figure 2. Coadministration of ALA attenuates MPTP induced
activation of ASK1, pMKK4 and pJNK. Animals were treated
with a single dose of vehicle or MPTP and sacrificed 12 h
later. Some animals also received a bidaily dose of ALA. A)
Representative blots from ventral midbrain (MB) and stria-
tum (ST) of animals treated with saline (lane 1), MPTP (lane
2), ALA (lane 3), and ALA  MPTP (lane 4), depicting the
protein levels of ASK1, phospho-MKK4 (p-MKK4), and phos-
pho-JNK (p-JNK) as determined by immunoblot are pre-
sented. -tubulin levels were measured as loading control. B)
Densitometric analysis of the immunoblots representing the
relative intensity of the immunoreactive bands are shown.
Values are mean 	 sd (n
3 animals). Asterisks indicate
values significantly different from corresponding control
(P0.05). The lanes are labeled as CMB—Control midbrain;
12MB—12 h MPTP treated midbrain; AMB—ALA treated
midbrain; AMMB—ALA  MPTP treated midbrain; CST—
control striatum; 12ST—12 h MPTP treated striatum; AMB—
ALA treated striatum; AMMB—ALA  MPTP treated stria-
tum.
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body weight, s.c.). Concomitantly, total GSH (repre-
sented as GSx) were reduced by 33% and this also led
to 28% loss in complex I activity (Fig. 3C). Thus,
reduction in GSH levels, as seen after PPG can, per se,
result in complex I inhibition.
Translocation of Daxx from nucleus to cytoplasm by
MPP in neuroblastoma cells and by MPTP, in vivo,
in mice
Daxx, the death-associated protein is a transcriptional
repressor that is normally present in the nucleus. Daxx
is known to translocate to cytoplasm, associate with
ASK1, and participate in the apoptotic process (27). We
treated human neuroblastoma cells with MPP and
examined the subcellular localization of Daxx. Treat-
ment with MPP for 12 h resulted in the translocation
of Daxx from nucleus to cytoplasm. However, when
cells were treated with N-acetyl cysteine or ALA for 1 h
prior to MPP, Daxx translocation could be prevented
(Fig. 4). We observed a similar translocation of Daxx
from the nucleus to the cytoplasm following MPTP
administration, in vivo in mice. Daxx translocates from
the nucleus to the cytosol in neurons in substantia nigra
pars compacta (Fig. 5; top panel B and C) but not in the
ventral tegmental area or substantia nigra pars reticu-
lata (Fig. 5; middle panel). Daxx was present predom-
inantly in the cytosol 24 h after administration of a
Figure 3. GSH and PrSSG levels in striatum and midbrain following MPTP
administration. A single dose of MPTP (30 mg/kg body weight, s.c) was
administered to mice, and animals were killed 4 h after dosage. Control animals
received vehicle alone. GSH and PrSSG levels were estimated in striatum and
midbrain using -glutamyl glutamate (-Gluglu) as internal standard. The
HPLC chromatogram (A) depicts the loss of GSH and increase in GSH
recovered as PrSSG in the striatum from MPTP treated mice. GSH levels are
significantly reduced by MPTP. B) GSH lost is essentially recovered as PrSSG.
GSH and PrSSG levels are expressed as nmoles of GSH/mg protein. Values are
mean	 sem (n
4 animals). Asterisks indicate values significantly different from
controls (P0.001). C) Inhibitor of -cystathionase, l-propargylglycine (PPG)
lowers GSH levels, and inhibits complex I activity in mouse brain. PPG (100
mg/kg body weight, s.c) was administered to mice, and animals were killed 18 h
later (white bar). Control animals received vehicle alone (black bar). Complex
I and -cystathionase activities and total GSH levels were estimated in the brain.
The activity of complex I is expressed as nmoles of NADH oxidized/min/mg
protein and -cystathionase activity is expressed as nmoles of cysteine formed/
hr/mg protein. GSH levels are expressed as nmoles of GSH/mg protein. Values
are mean 	 sem (n
6 animals). Asterisks indicate values significantly different
from controls (P0.002).
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single dose of MPTP (Fig. 5; middle panel) and also in
the surviving neurons after subchronic treatment of
MPTP for 8 d (Fig. 5; middle panel). ALA coadminis-
tration could abolish these effects, and Daxx was essen-
tially present in the nucleus (Fig. 5; middle panel).
These observations were validated by visualizing Daxx
immunostaining with FITC and costaining the sections
with DAPI (Fig. 5; bottom panel), wherein the translo-
cation of Daxx to the cytosol following MPTP adminis-
tration is clearly discernable.
DJ-1 was down-regulated in a region specific manner
following MPTP treatment
DJ-1, an antioxidant responsive protein interacts with
Daxx in the nucleus and helps the sequestration of
Daxx within the nucleus, preventing its translocation to
the cytoplasm (28). We observed selective down-regu-
lation of DJ-1 in the postnuclear supernatant prepared
from ventral midbrain but not striatum following MPTP
exposure, which was prevented by -lipoic acid treat-
ment (Fig. 6A). Importantly, DJ-1 levels were also
significantly lower in the nuclear extracts prepared
Figure 5. Translocation of Daxx to the cytosol in dopaminergic
neurons of SNpc following administration of MPTP to mice.
Animals were treated with a single dose of MPTP and sacrificed
24 h later. Animals were also treated with a daily dose of MPTP
for 8 d and sacrificed on the 9th day. Two subsets of animals were
coadministered -lipoic acid twice daily. Immunohistochemical
localization of Daxx revealed the translocation of Daxx to the
cytosol in SNpc neurons after MPTP exposure. Daxx is present
in the nucleus in control animals (A), while it is present in the
cytoplasm following a single dose of MPTP (B), and in the
surviving neurons after subchronic exposure to MPTP for 8 d
(C). D–F) depict the subcellular localization of Daxx in corre-
sponding group of animals coadministered ALA, wherein, Daxx
is localized essentially in the nucleus. Scale bar
 25 m. a–f) Of
the lower panel show corresponding magnified images of the
neurons indicated by arrowheads in the upper panel. The
panels indicated by VTA and SNR depict the presence of Daxx
in the nucleus in the ventral tegmental area (VTA) and substan-
tia nigra pars reticulata (SNR) neurons following acute and
subchronic MPTP exposure. Scale Bar 
 10 m. Immunofluo-
rescent images for Daxx (green) also show the similar pattern of
translocation of Daxx to the cytosol following a single dose of
MPTP, which is prevented by ALA. Cells were counterstained
with DAPI prior to mounting. Scale Bar 
 10 m.
Figure 4. Daxx translocates from nucleus to the cytosol
following exposure to MPP in SH-SY5Y human neuroblas-
toma cells.Cells were exposed for 12 h to MPP alone (3 mM)
or in combination with N-acetyl cysteine (NAC; 100 M) or
ALA (ALA; 100 M) and then immunostained for Daxx. Cells
were counterstained with DAPI prior to mounting. On expo-
sure to MPP Daxx translocated to cytosol, which was pre-
vented by prior treatment with NAC or ALA. Scale bar 

120 m.
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from ventral midbrain of MPTP treated animals (Fig.
6B).
ALA abolishes MPTP mediated complex I inhibition
in male mice and attenuates dopaminergic cell loss
in SNpc
We then examined the effect of coadministration of
ALA on the number of surviving dopaminergic neurons
in SNpc (Fig. 7A–D) and mitochondrial complex I
activity (Fig. 7F) following subchronic MPTP treatment
for 8 d. Coadministration of ALA attenuated MPTP-
mediated dopaminergic cell loss in SNpc measured by
stereological analysis of dopaminergic neurons identi-
fied as tyrosine hydroxylase positive cells (Fig. 7E). In
animals treated with MPTP alone, 24% of cell loss was
seen after 8 d of MPTP (Fig. 7B), while in animals
coadministered ALA, the cell loss was only 11%, indi-
cating the significant protection offered by ALA (Fig.
7E). Coadministration of ALA with MPTP also abol-
ished complex I inhibition in striatum and ventral
midbrain, which is a hallmark of MPTP toxicity (Fig.
7F).
MPP levels in ventral midbrain following MPTP
administration
MPP levels were measured in ventral midbrain at 1
and 12 h following a single dose of MPTP with and
without ALA coadministration (Fig. 8). Significant
amounts of MPP were present in ventral midbrain 1 h
after MPTP exposure (Fig. 8). Further, coadministra-
tion of ALA had no effect on MPP levels in ventral
midbrain, indicating that ALA did not alter the biodis-
tribution of MPP. MPP was not detectable 12 h after
MPTP administration, indicating its rapid clearance
from the ventral midbrain.
DISCUSSION
ASK1, a mitogen activated protein (MAP) kinase kinase
kinase, is 160 kDA protein that functions as a serine
threonine kinase. ASK1 is sensitive to reactive oxygen
species and activates p38 and JNK by directly phosphor-
ylating mitogen activated kinase kinases, MKK3/6 and
MKK4/7 (15). ASK1 has two regulatory domains at the
N- and C-terminal, while the kinase domain is present
in the middle of the molecule. Thioredoxin (Trx)
binds to the N-terminal domain and prevents the
oligomerization and autophosphorylation of ASK1,
which initiates the proapoptotic cascade. Overexpres-
sion of ASK1 (both wild-type and the constitutively
active N-terminal truncated form) enhances ROS-me-
diated death in cultured cells, including that induced
by 6-hydroxy dopamine (29), while apoptosis is sup-
pressed in ASK1 knockout cells.
Exposure of mice to MPTP activated ASK1 and led to
the phosphorylation of the downstream kinases
namely, SEK1/MKK4 and JNK (Fig. 2). Phosphoryla-
tion of JNK has been identified as a key mediator of cell
death in animal models of Parkinson’s disease and
pretreatment with JNK inhibitors attenuates dopami-
nergic cell loss (30, 31). However, there is no informa-
tion on the upstream events leading to JNK activation.
We show here that activation of ASK1 may be the
trigger for JNK activation. Since oxidative modification
of Trx dissociates it from ASK1, resulting in the activa-
tion of ASK1 through oligomerization and autophos-
phorylation (32, 33), we examined if the thiol antioxi-
dant ALA could prevent ASK1 activation by presumably
maintaining the redox status of Trx. ALA abolishes the
activation of ASK1 mediated by MPTP, indicating that
oxidative stress is presumably the trigger for ASK1
activation, resulting in phosphorylation of MKK4,
which in turn phosphorylates JNK (Fig. 2).
Daxx, the death-associated protein and transcrip-
tional repressor, translocates from the nucleus to the
cytosol and associates with ASK1 propagating the death-
signaling cascade (34). Daxx is presumably phosphor-
ylated through ASK1-SEK1-JNK1 (35), which results in
its translocation to the cytosol and association with
ASK1. We examined the cellular status of Daxx, in vitro,
using SH-SY5Y, the human neuroblastoma cell line.
Figure 6. DJ-1 is down-regulated in ventral midbrain following
MPTP treatment. Animals were treated with a single dose of
vehicle or MPTP and sacrificed 12 h later. Some animals also
received ALA twice daily. A) Representative immunoblot of
extranuclear DJ-1 from ventral midbrain (MB) and striatum
(ST) of animals treated with saline (lane 1), MPTP (lane 2),
ALA (lane 3), and ALA  MPTP (lane 4) is depicted.
-Tubulin levels were measured as loading control. Densito-
metric analysis of the immunoblots representing the relative
intensity of the immunoreactive bands DJ-1 bands shows the
down-regulation of DJ-1 by MPTP which is prevented by ALA.
B) DJ-1 levels in the nucleus are down-regulated 12 h after a
single dose of MPTP. Representative immunoblot and densi-
tometric analysis of the immunoblots representing the rela-
tive intensity of the immunoreactive bands of nuclear DJ-1 is
depicted. Lamin was used as loading control. Values are
mean 	 sd (n
3 animals). Asterisks indicate values signifi-
cantly different from corresponding control (P0.05). The
lanes are depicted as CMB—control midbrain; 12MB—12 h
MPTP treated midbrain; AMB—ALA treated midbrain;
AMMB—ALA  MPTP treated midbrain; CST—control stri-
atum; 12ST—12 h MPTP treated striatum; AMB—ALA
treated striatum; AMMB—ALA  MPTP treated striatum.
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Exposure to MPP resulted in translocation of Daxx,
which was prevented by thiol antioxidants, such as
N-acetyl cysteine (NAC) or ALA (Fig. 4). We then
examined the cellular localization of Daxx in SNpc of
mice treated with MPTP. Daxx translocated from nu-
cleus to cytoplasm in SNpc neurons 24 h after a single
dose of MPTP. Coadministration of ALA abrogated
Daxx translocation to the cytosol. Further, in animals
treated subchronically with MPTP for 8 d, a major
portion of Daxx was seen in the cytosol in most of the
surviving neurons in SNpc, while it was in the nucleus
in majority of neurons in animals treated with both
ALA and MPTP (Fig. 5). Further, the translocation of
Daxx was seen predominantly in SNpc neurons that are
affected by MPTP and in Parkinson’s disease but not in
the adjacent dopaminergic neurons in ventral tegmen-
tal area or in the substantia nigra pars reticulata that
are unaffected by MPTP (Fig. 4). This is the first
demonstration of Daxx translocation, in vivo, and the
functional implications thereof. Daxx has been shown
to translocate to the cytosol following exposure to
-amyloid peptide, in vitro, in cells, in a manner similar
to that seen with hydrogen peroxide (36), but in vivo
evidence has been lacking so far.
Note that after a single dose of MPTP, complex I
activity recovers completely at 24 h (24). However, we
find that Daxx continues to be present in the cytosol at
this time point, indicating that the death pathway
trigger persists longer after a single dose compared to
the mitochondrial dysfunction measured as complex I
activity. Further, after subchronic dosing with MPTP for
8 d, while ALA completely abolished complex I loss it
was able to attenuate, but not abolish, dopaminergic
cell loss. Presumably, ALA was unable to afford com-
plete protection against cell death, indicating that a
more potent antioxidant thiol was essential to com-
pletely block the MAPK death cascade.
MPP, the toxic metabolite of MPTP, directly inhib-
its complex I by binding to the rotenone binding site of
complex I and also indirectly by generating oxidative
stress. The recovery of complex I activity 24 h after
MPTP is concordant with the absence of detectable
MPP in the ventral midbrain 12 h after MPTP (Fig. 8).
Thus, it appears that MPP is rapidly cleared from the
ventral midbrain.
DJ-1 (PARK 7) is a redox-sensitive protein that has
been implicated in certain familial forms of PD (37).
DJ-1 has a redox sensitive cysteine residue (Cys106) that
Figure 7. -Lipoic acid attentuates MPTP-in-
duced loss of dopaminergic neurons in SNpc
and abolishes MPTP-mediated inhibition of
complex I activity in mice. Tyrosine hydroxy-
lase immunostaining of dopaminergic neurons
in the substantia nigra of mice treated with
vehicle (A), MPTP (B), ALA (C), or both ALA
and MPTP (d) for 8 d as described above. Scale
bar – 50 m. E) Quantitative stereological anal-
ysis of the tyrosine hydroxylase positive neu-
rons’ profile from saline or ALA (black bars) and
MPTP or ALA  MPTP (gray bars). Values are
mean 	 sem (n
5). Asterisks indicate values
significantly different from respective controls
(P0.01). Complex I activity was measured in
the striatum and ventral midbrain (F). Com-
plex I activity is expressed as nmoles of NADH
oxidized/min/mg protein. Values are mean 	
sd (n
6 animals) and asterisks indicate values
significantly different from vehicle treated con-
trols (P0.002).
2233Daxx AND ASK1, A MAPKKK IN MPTP TOXICITY
is oxidatively modified following exposure to ROS (38).
Although the role of Daxx in cell death is controversial,
recent studies have shown that DJ-1 is associated with
Daxx in the nucleus and this association prevents the
translocation of Daxx to the cytosol (28). Mutations in
DJ-1 that lead to familial Parkinson’s disease prevent its
association with Daxx in the nucleus. Here we find that
MPTP exposure down-regulates DJ-1 levels, both in the
nucleus and in the extranuclear compartments (Fig. 6).
Thus, presumably the lowered levels of DJ-1 in the
nucleus result in the dissociation of Daxx from DJ-1,
leading to its translocation and association with ASK1
in the cytosol propagating the death cascade. This
represents another mechanism of Daxx translocation
in addition to that through its phosphorylation by JNK
(39).
In this study, we demonstrate the potential of the
thiol delivery agent, ALA to protect against the activa-
tion of apoptosis signaling pathway, the mitochondrial
dysfunction and attentuate dopaminergic cell loss, in
vivo, in mice. Although the protective effect of ALA has
been described in vitro, in cultured cells (40), this is the
first demonstration of its effect in an animal model of
Parkinson’s disease.
One of the primary effects of MPTP exposure is
generation of oxidative stress leading to perturbation of
thiol homeostasis seen as glutathione (GSH) loss and
extensive modification of thiol groups in proteins. The
lack of increase in glutathione disulphide (GSSG)
levels following oxidative stress seems to indicate that
the protein glutathione mixed disulfide (PrSSG) for-
mation presumably occurs through formation of
sulfenic acids as downstream effect of the oxidative
stress generated by MPTP (Fig. 3B). Oxidative stress is
a primary effect of MPTP, which can lead to dysfunc-
tion of complex I since complex I is extremely sensitive
to the perturbation of thiol homeostasis (41). We
down-regulated GSH levels using the inhibitor of cysta-
thionine -lyase L-propargylglycine (PPG), since the
commonly used inhibitor of -glutamyl-cysteine syn-
thase, buthionine sulfoximine, does not cross the blood
brain barrier. Cystathionine -lyase is the last enzyme of
the transsulfuration pathway that synthesizes cysteine
from methionine. Availability of cysteine is critical for
GSH synthesis. PPG reduced GSH levels and inhibited
complex I activity (Fig. 3C), which could be reversed by
the disulfide reductant, dithiothreitol (8), indicating
that oxidation of protein thiol groups are responsible
for the loss of enzyme activity. These studies were
initially performed in Swiss Albino mice, but since the
C57BL6J mice are known to be more sensitive to
MPTP-mediated cell loss, experiments that addressed
cell death were performed using C57BL6J mice. We
hypothesize that generation of oxidative stress leading
to perturbation of protein thiols is a primary effect of
MPTP, which is a causative factor not only for complex
I dysfunction but can also trigger the activation of
death pathway through activation of key signaling path-
ways triggered by redox perturbation, which are in-
volved in the initiation of cell death cascade (Fig. 9).
Our studies demonstrate the activation of MAPK
signaling cascade and translocation of Daxx in specific
regions of the brain (namely ventral midbrain and
striatum) following MPTP administration, in vivo, in
mice. ALA prevents these effects, indicating that they
are triggered by oxidative stress. Oxidative stress and
the protein thiol modification resulting from MPTP
exposure induce mitochondrial dysfunction via com-
Figure 8. MPP levels in ventral midbrain fol-
lowing MPTP administration. MPP levels were
measured in ventral midbrain following MPTP
administration. HPLC chromatogram depict-
ing standard MPP (A), and MPP levels 1 (B,
C) and 12 h (D) after a single dose of MPTP.
Some animals were also administered with so-
dium salt of -lipoic acid (ALA; 22 mg/kg body
weight, s.c.) 1 h prior to MPTP injection (C).
MPP concentration was similar in both the
groups namely those treated with MPTP alone
or with both ALA and MPTP (E; n
3).
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plex I inhibition and also trigger the MAPK pathway
through activation of ASK1 (Fig. 9). Complex I inhibi-
tion can further generate oxidative stress propagating
the cell death pathway. Thus, these effectors feed on
each other presumably leading to the untimely demise
of dopaminergic neurons. Thiol delivery agents offer
an attractive option for terminating this cascade and
protecting the further loss of dopaminergic neurons in
Parkinson’s disease.
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